The Administration Core will provide executive oversight and administrative support for all of the projects and cores that comprise the Leukemia SPORE. The goal of the Administration Core is to monitor the activities of all of the program components, to comply with all local and federal guideline for grant administration, and to facilitate communication and collaboration among the program members and with other Leukemia SPOREs. Accordingly, the specific aims of the Administration Core are as follows:
Aim 1. To facilitate intra- and inter-SPORE communication and collaboration.
Aim 2. To provide administrative and fiscal oversight and support for all SPORE components.
Aim 3. To coordinate administrative activities of the SPORE Developmental Research Program.
Aim 4. To coordinate the SPORE Career Enhancement Program.
Aim 5. To assist investigators with the preparation of scholarly presentations, publications, regulatory documents, and all other SPORE-related paperwork.
Aim 6. To enhance participation of minorities in SPORE activities.
Aim 7. To ensure advocacy issues are addressed and included in all aspects of research with patient participants.

Public Health Relevance

(2-3 SENTENCES) This shared resource will provide needed administrative support for the translational leukemia research proposed in this SPORE and facilitate collaboration between other SPORE institutions.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Saint Louis
United States
Zip Code
Wagner, Julia A; Berrien-Elliott, Melissa M; Rosario, Maximillian et al. (2017) Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and Fc?RIIIa-Triggered Responses. Biol Blood Marrow Transplant 23:398-404
Uy, G L; Duncavage, E J; Chang, G S et al. (2017) Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia 31:872-881
Saez, Borja; Walter, Matthew J; Graubert, Timothy A (2017) Splicing factor gene mutations in hematologic malignancies. Blood 129:1260-1269
Cooper, Matthew L; Choi, Jaebok; Karpova, Darja et al. (2017) Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo. J Immunol 198:3746-3754
Duncavage, Eric J; Uy, Geoffrey L; Petti, Allegra A et al. (2017) Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. Blood 129:1397-1401
Shirai, Cara Lunn; White, Brian S; Tripathi, Manorama et al. (2017) Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat Commun 8:14060
Schroeder, Mark A; Choi, Jaebok; Staser, Karl et al. (2017) The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. Biol Blood Marrow Transplant :
How, Joan; Slade, Michael; Vu, Khoan et al. (2017) T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. Biol Blood Marrow Transplant 23:648-653
Ali, Alaa M; Weisel, Daniel; Gao, Feng et al. (2017) Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. Cancer Med 6:2814-2821
Romee, Rizwan; Rosario, Maximillian; Berrien-Elliott, Melissa M et al. (2016) Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med 8:357ra123

Showing the most recent 10 out of 44 publications